KRAS and lung adenocarcinoma: The detection rates of the ALK KD screening test are similar to those reported by Shaw AT., et al. [4] (approximately 13%), who focused on a subset of patients without EGFR and KRAS gene mutations, but substantially higher than those reported by Soda et al. [3] (approximately 5%), who examined patients with unselected lung adenocarcinoma.